Genus PLC
LSE:GNS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Genus PLC
Other Current Liabilities
Genus PLC
Other Current Liabilities Peer Comparison
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Genus PLC
LSE:GNS
|
Other Current Liabilities
ÂŁ65.8m
|
CAGR 3-Years
78%
|
CAGR 5-Years
49%
|
CAGR 10-Years
25%
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Other Current Liabilities
$112k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exscientia PLC
NASDAQ:EXAI
|
Other Current Liabilities
ÂŁ29.1m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Other Current Liabilities
$533k
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Other Current Liabilities
$16.6m
|
CAGR 3-Years
18%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other Current Liabilities
ÂŁ0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Genus PLC's Other Current Liabilities?
Other Current Liabilities
65.8m
GBP
Based on the financial report for Dec 31, 2023, Genus PLC's Other Current Liabilities amounts to 65.8m GBP.
What is Genus PLC's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
25%
Over the last year, the Other Current Liabilities growth was -14%. The average annual Other Current Liabilities growth rates for Genus PLC have been 78% over the past three years , 49% over the past five years , and 25% over the past ten years .